In Competition Law and Policy Debate, Raphaël De Coninck highlights the European Commission’s recent interest in assessing the impact of pharmaceutical mergers on innovation. The article discusses the Commission’s approach and argues in favor of developing a consistent framework for assessing the impact of mergers on innovations. To read more, click the link below.
CRA experts nominated for prestigious 2026 Antitrust Writing Awards
The Editorial Committee selected the top academic and business articles published in the past year. These awards honor originality, contribution to competition...